HRAS and breast carcinoma: The top five CTRP hits in rank order include ML239 (breast cancer stem cell inhibitor), Niclosamide (anti tapeworm drug), Tipifarnib (H-Ras inhibitor), CHIR-99021 (GSK-3α/β inhibitor), and Tivantinib (MET inhibitor).